參麥注射液在頭頸部腫瘤放療中減輕放射性不良反應的臨床觀察

陳飛　余婷婷　劉曉安

[摘要] 目的 觀察參麥注射液在頭頸部腫瘤放療中減輕放射性不良反應的臨床效果。 方法 分析2015年3月～2017年3月我院收治的128例頭頸部腫瘤放療患者的臨床資料，計算總有效率；總的放療2～4級急性損傷發生率、中重度疼痛發生率、生活質量降低發生率；放療完成1個月后的生活質量改善發生率。 結果 觀察組患者治療的總有效率[93.75%（60/64）]明顯高于對照組[81.25%（52/64）]，差異具有統計學意義（P<0.05）；總的放療2～4級急性損傷發生率明顯低于對照組，差異具有統計學意義（P<0.05），中重度疼痛發生率31.25%（20/64）明顯低于對照組的68.75%（44/64），差異具有統計學意義（P<0.05）；放療完成1個月后觀察組患者的生活質量改善發生率93.75%（60/64），明顯高于對照組62.50%（40/64），差異具有統計學意義（P<0.05），觀察組患者生活質量降低發生率0%（0/64），明顯低于對照組的15.63%（10/64），差異具有統計學意義（P<0.05）。 結論 參麥注射液在頭頸部腫瘤放療中減輕放射性不良反應的臨床效果顯著。

[關鍵詞] 參麥注射液；頭頸部腫瘤放療；臨床療效；放射性不良反應

[中圖分類號] R273 [文獻標識碼] B [文章編號] 1673-9701（2017）28-0095-03

[Abstract] Objective To observe the clinical effect of Shenmai injection on reducing radioactive adverse reactions in head and neck tumor radiotherapy. Methods The clinical data of 128 patients with head and neck tumor radiotherapy who were admitted to our hospital from March 2015 to March 2017 were statistically analyzed. The total effective rate was calculated； total incidence rate of grade 2-4 acute injury by radiotherapy； incidence rate of moderate to severe pain； incidence rate of quality of life reduction； incidence rate of improvement in quality of life after one month of radiotherapy were compared. Results The total effective rate was 93.75%（60/64） in the observation group， which was significantly higher than that of 81.25%（52/64） in the control group，the difference was significant（P<0.05）； the total incidence rate of grade 2-4 acute injury was significantly lower than that in the control group，the difference was significant（P<0.05）. The incidence rate of moderate to severe pain was 31.25%（20/64）， which was significantly lower than that of 68.75%（44/64） in the control group， the difference was significant（P<0.05）； the improvement rate of quality of life in the observation group was 93.75%（60/64）， the difference was significant， which was significantly higher than that of 62.50%（40/64） in the control group， the difference was significant（P<0.05）. The incidence rate of life quality reduction was 0%（0/64） in the observation group， which was significantly lower than that of 15.63%（10/64） in the control group， the difference was significant（P<0.05）. Conclusion Shenmai injection in the head and neck tumor radiotherapy has a significant clinical effect of reducing radioactive adverse effects.

[Key words] Shenmai injection； Head and neck tumor radiotherapy； Clinical efficacy； Radioactive adverse reactions

放射治療為頭頸部惡性腫瘤重要的治療手段，雖然放療的設備和技術有了長足的進步，如適形、調強、立體定向放療，但無法避免放療的毒副反應及并發癥的發生，因此放療過程中出現的不良反應常使患者中斷治療，使療效降低，病程延長，患者生存質量嚴重下降。祖國醫學認為放射線是火熱陽毒之邪，可傷陰耗氣，灼傷津液，而參麥注射液屬于純中藥抗癌藥物，主要功效為清熱解毒、鎮痛等[1]。本研究對2015年3月～2017年3月我院收治的128例頭頸部腫瘤放療患者的臨床資料進行統計分析，觀察參麥注射液在頭頸部腫瘤放療中減輕放射性不良反應的臨床效果，現報道如下。endprint